DK2470540T3 - Hidtil ukendte former af en multicyklisk forbindelse - Google Patents

Hidtil ukendte former af en multicyklisk forbindelse Download PDF

Info

Publication number
DK2470540T3
DK2470540T3 DK10750210.6T DK10750210T DK2470540T3 DK 2470540 T3 DK2470540 T3 DK 2470540T3 DK 10750210 T DK10750210 T DK 10750210T DK 2470540 T3 DK2470540 T3 DK 2470540T3
Authority
DK
Denmark
Prior art keywords
compound
xrpd
forms
crystalline
hdo
Prior art date
Application number
DK10750210.6T
Other languages
English (en)
Inventor
Stephen Bierlmaier
Michael Christie
Laurent Courvoisier
R Scott Field
R Curtis Haltiwanger
Linli He
Martin J Jacobs
Michael Kress
Robert E Mckean
Dale R Mowrey
Joseph Petraitis
Mehran Yazdanian
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2470540(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK2470540T3 publication Critical patent/DK2470540T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (7)

1. Krystallinsk form af Forbindelse I med formlen
hvor den krystallinske form er: (A) a. Form Ao som er kendetegnet ved et røntgen-pulverdiffraktionsmønster omfattende en eller flere af de følgende toppe: 4,32, 6,07, 8,55, 12,07 og 15,37 ± 0,2 grader 2-theta; eller (B) a. Form HCo som er kendetegnet ved et røntgenpulverdiffraktionsmønster omfattende en eller flere af de følgende toppe: 8,36, 8,71, 16,69, 17,39 og 24,59 ± 0,2 grader 2-theta; eller b. Form HDo som er kendetegnet ved et røntgenpulverdiffraktionsmønster omfattende en eller flere af de følgende toppe: 7,60, 8,99 og 15,16 ± 0,2 grader 2-theta; eller en blanding deraf.
2. Krystallinsk form af Forbindelse I ifølge krav 1, hvor den krystallinske form er Form Ao.
3. Krystallinsk form af Forbindelse I ifølge krav 1, hvor den krystallinske form er Form HCo.
4. Krystallinsk form af Forbindelse I ifølge krav 1, hvor den krystallinske form er Form HDo.
5. Farmaceutisk sammensætning omfattende en krystallinsk form af Forbindelse I ifølge et hvilket som helst af kravene 2 til 4, eller en blanding deraf.
6. Farmaceutisk sammensætning ifølge krav 5, hvor den farmaceutiske sammensætning er en blanding deraf.
7. Farmaceutisk sammensætning ifølge krav 5 eller 6, hvor sammensætningen yderligere omfatter en amorf form af Forbindelse I.
DK10750210.6T 2009-08-26 2010-08-25 Hidtil ukendte former af en multicyklisk forbindelse DK2470540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718009P 2009-08-26 2009-08-26
PCT/US2010/046671 WO2011028580A1 (en) 2009-08-26 2010-08-25 Novel forms of a multicyclic compound

Publications (1)

Publication Number Publication Date
DK2470540T3 true DK2470540T3 (da) 2016-08-01

Family

ID=43033463

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10750210.6T DK2470540T3 (da) 2009-08-26 2010-08-25 Hidtil ukendte former af en multicyklisk forbindelse

Country Status (20)

Country Link
US (1) US8633314B2 (da)
EP (1) EP2470540B1 (da)
JP (3) JP2013503173A (da)
KR (1) KR20120092100A (da)
CN (1) CN102482282A (da)
AU (1) AU2010289746B2 (da)
BR (1) BR112012004053A2 (da)
CA (1) CA2772328C (da)
CL (1) CL2012000478A1 (da)
DK (1) DK2470540T3 (da)
EA (1) EA020756B1 (da)
ES (1) ES2572652T3 (da)
HK (1) HK1171750A1 (da)
IL (1) IL218132B (da)
MX (1) MX2012002456A (da)
MY (1) MY156873A (da)
NZ (1) NZ598883A (da)
SG (1) SG178852A1 (da)
UA (1) UA110604C2 (da)
WO (1) WO2011028580A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028580A1 (en) * 2009-08-26 2011-03-10 Cephalon, Inc. Novel forms of a multicyclic compound
EP3224259A1 (en) * 2014-11-26 2017-10-04 Cephalon, Inc. Crystalline forms of parp inhibitors
KR20200014736A (ko) 2017-03-27 2020-02-11 테사로, 인코포레이티드 니라파립 조성물
MA50657A (fr) 2017-09-26 2020-08-05 Tesaro Inc Formulations de niraparib
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
BRPI0615096A2 (pt) * 2005-08-24 2009-07-14 Inotek Pharmaceuticals Corp análogos de indenoisoquinolinona e métodos de uso dos mesmos
JP5542444B2 (ja) * 2006-11-20 2014-07-09 セファロン、インク． 放射線増感剤を用いた放射線感受性腫瘍に対する方法
WO2011028580A1 (en) * 2009-08-26 2011-03-10 Cephalon, Inc. Novel forms of a multicyclic compound

Also Published As

Publication number Publication date
JP2013503173A (ja) 2013-01-31
AU2010289746B2 (en) 2016-07-07
US8633314B2 (en) 2014-01-21
JP2018035158A (ja) 2018-03-08
IL218132B (en) 2018-02-28
CN102482282A (zh) 2012-05-30
ES2572652T3 (es) 2016-06-01
WO2011028580A1 (en) 2011-03-10
IL218132A0 (en) 2012-06-28
EA020756B1 (ru) 2015-01-30
MX2012002456A (es) 2012-05-08
HK1171750A1 (zh) 2013-04-05
CA2772328C (en) 2017-06-20
CA2772328A1 (en) 2011-03-10
NZ598883A (en) 2014-09-26
SG178852A1 (en) 2012-04-27
EP2470540B1 (en) 2016-04-20
UA110604C2 (uk) 2016-01-25
CL2012000478A1 (es) 2012-11-05
EA201270315A1 (ru) 2012-08-30
BR112012004053A2 (pt) 2020-12-08
AU2010289746A1 (en) 2012-04-12
KR20120092100A (ko) 2012-08-20
JP2016014029A (ja) 2016-01-28
EP2470540A1 (en) 2012-07-04
US20120214998A1 (en) 2012-08-23
MY156873A (en) 2016-04-15

Similar Documents

Publication Publication Date Title
US11384086B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
JP2018035158A (ja) 多環系化合物の新規形態
US11168057B2 (en) Polymorphs and co-crystals of roxadustat
US8501960B2 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
JP2022137223A (ja) セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス
WO2014008794A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
EP2729470B1 (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
JP2009513582A (ja) ４−オキソ−１−（３置換フェニル）−１，４−ジヒドロ−１，８−ナフチリジン−３−カルボキサミドホスホジエステラーゼ４阻害剤及びその製造方法
CN105246892B (zh) 结晶化合物
WO2017206827A1 (zh) 钠-葡萄糖协同转运蛋白2抑制剂的晶型
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂
CN1938306A (zh) 5,11－二氢－11－乙基－5－甲基－8－{2－{(1－氧－4－喹啉基)氧基}乙基}－6H－二吡啶并[3,2－b:2′,3′－e][1,4]二氮杂䓬－6－酮的晶形
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
WO2012153349A2 (en) Rasagiline and its pharmaceutically acceptable salts
AU2019240721A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
MX2011005055A (es) Nuevas formas de un compuesto de indazolo [5,4-a]pirrolo[3,4-c]car bazol.
WO2014063752A1 (en) Process for making crystalline form alpha of eletriptan hydrobromide